Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




New 'Protein Nano-Switch' Method Paves Way for Faster, More Accurate Diagnostic Tests

By LabMedica International staff writers
Posted on 02 Aug 2023

Presently, 'point of care' diagnostic tests that offer results on the spot, such as those for blood sugar, pregnancy, and COVID-19, utilize protein-sensing systems to detect sugar, pregnancy hormones, and COVID-19 proteins. More...

However, these tests make up only a small part of the requirements in a patient-centric healthcare model. The creation of new sensing systems is a demanding and lengthy task that involves significant trial and error. Researchers have now developed a new 'protein nano-switch' technique that significantly accelerates the development of similar diagnostic tests by reducing the required time and boosting success rates.

A multidisciplinary research team that included scientists from Queensland University of Technology (QUT, Brisbane, Australia) has developed an approach for designing molecular ON-OFF switches based on proteins that can be applied in numerous biotechnological, biomedical, and bioengineering settings. This innovative method which allows researchers to develop more rapid and accurate diagnostic tests involves using modified proteins to act like ON/OFF switches in response to specific targets. The key advantage is that the system is modular, much like building with Lego blocks, allowing for easy replacement of parts to target different elements—such as a different drug or a medical biomarker.

The new protein-engineering technology offers a unique way to create lab tests. It offers the potential to construct various diagnostic and analytic tests with a broad array of possible applications, including human and animal health diagnostics. The researchers demonstrated their technology by focusing on a cancer chemotherapy drug that is toxic and must be frequently measured to ensure patient safety. The sensor they designed for this drug uses a color change to identify and measure the drug. The next stage would involve testing the sensor for clinical use approval. The researchers intend to standardize and scale this approach and begin creating more complex subsystems. According to the researchers, there are two potential paths for future work.

"One is to develop computer models that allow us to design and build the switches even more rapidly and precisely," said Professor Kirill Alexandrov, of the QUT School of Biology and Environmental Science. "The other is to demonstrate the scale and potential of the technology by building many switches for different diagnostic applications."

Related Links:
QUT 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.